Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

64.18EUR
15 Dec 2017
Change (% chg)

€-0.40 (-0.62%)
Prev Close
€64.58
Open
€64.38
Day's High
€64.56
Day's Low
€63.93
Volume
3,943,400
Avg. Vol
1,447,066
52-wk High
€80.07
52-wk Low
€60.15

Chart for

About

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments... (more)

Overall

Beta: 0.60
Market Cap(Mil.): €35,598.51
Shares Outstanding(Mil.): 554.67
Dividend: 0.62
Yield (%): 0.97

Financials

  Industry Sector
P/E (TTM): -- 28.82 16.04
EPS (TTM): -- -- --
ROI: -- 7.96 34.69
ROE: -- 11.65 15.46

Deals of the day-Mergers and acquisitions

Nov 22 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:

Nov 22 2017

Fresenius says on track to increase dividend again next year

FRANKFURT, Nov 21 German healthcare group Fresenius SE is well on its way to further increase its annual dividend next year, reflecting the prospect of earnings growth in 2017, its chief executive said.

Nov 21 2017

U.S. fights Fresenius dismissal bid in Medicare billing case

The U.S. Justice Department is urging a federal judge not to dismiss some of its claims that kidney dialysis services company Fresenius SE & Co KGaA billed Medicare for medically unnecessary tests.

Nov 13 2017

Fresenius wins document unsealing in U.S. false claims case

Fresenius SE & Co KGaA has secured an order to unseal portions of court documents filed by the U.S. Justice Department relating to its investigation of a whistleblower complaint accusing the kidney dialysis services company of billing for medically unnecessary services.

Nov 09 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

Oct 26 2017

UPDATE 3-Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON, Oct 26 The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

Oct 26 2017

Senvest Management shorting drug stocks Insys, Akorn, Fresenius

TEL AVIV, Oct 3 New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday,

Oct 03 2017

BRIEF-Fresenius refinances 3.8 bln euro credit agreement

* Credit agreement has volume of around 3.8 billion euros, consists of revolving facilities and term loans with maturities in 2021 and 2022

Aug 24 2017

Fresenius Q2 adjusted earnings jump on new drug launches

FRANKFURT, Aug 1 Diversified German healthcare group Fresenius, controlled by a charitable trust, saw adjusted net income jump 21 percent, bolstered by new drug launches at its U.S. generic infusion division Kabi and by newly-acquired Quironsalud, Spain's largest hospital chain.

Aug 01 2017

Fresenius poaches Telefonica Deutschland CFO Rachel Empey

BERLIN, July 21 Fresenius named Rachel Empey as its chief financial officer on Friday, poaching her from Telefonica Deutschland.

Jul 21 2017

Earnings vs. Estimates